Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

91.89 -2.52 (-2.67%)
Official Closing Price Updated: 7:00 PM EDT, Jun 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,524,075
Open 94.11
Bid (Size) 91.10 (2)
Ask (Size) 92.18 (2)
Prev. Close 94.41
Today's Range 91.47 - 94.33
52wk Range 70.89 - 95.72
Shares Outstanding 2,531,374,696
Dividend Yield 2.83%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
More than four in 10 people in a recent survey knew of someone with long Covid. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga

Performance

YTD
+19.54%
+19.54%
1 Month
-0.15%
-0.15%
3 Month
+12.65%
+12.65%
6 Month
+19.63%
+19.63%
1 Year
+19.56%
+19.56%

More News

Read More
8 Analysts Have This to Say About Merck & Co
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Via Benzinga
Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ
Via Benzinga
Merck To Start Pivotal Trial For Next-Gen Pneumococcal Vaccine Next Month
Via Benzinga
Tesla To $1,150? Here's The Biggest Price Target Changes For Monday
Via Benzinga
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
From Merck & Co., Inc.
Via Business Wire
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
Via Benzinga
3 Dow Stocks to Buy for a Bear Market
Via InvestorPlace
Seagen Surges As Merck Takeover Deal Reportedly Accelerating
Via Investor's Business Daily
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24
Via Benzinga
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
From Merck & Co., Inc.
Via Business Wire
Merck & Co Whale Trades For June 23
Via Benzinga
6 Dividend Income Stocks With Better Yields Than the S&P 500
Via InvestorPlace
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Via Benzinga
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
Via InvestorPlace
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Via Benzinga
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
From Merck & Co., Inc.
Via Business Wire
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
From Merck & Co., Inc.
Via Business Wire
SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know
Via Benzinga
Tackling Recurring Health Conditions Offers Hope to Patients
Via FinancialNewsMedia
Jupiter Wellness Believes Its Latest Strategic Acquisition Could Be A Significant Boon To Compete In The Medical Cannabis Industry
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.